Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tiaozhi Tongmai Granule is a Traditional Chinese Medicine (TCM) formulation developed for the treatment of cardiovascular and metabolic disorders, specifically atherosclerosis and carotid atherosclerosis. The formulation is designed to regulate blood lipids and improve vascular patency by addressing phlegm-dampness and blood stasis according to TCM principles. It is currently being evaluated in clinical research, such as trial ChiCTR2200059324, to assess its efficacy in reducing carotid intima-media thickness and improving lipid profiles in patients with dyslipidemia and early-stage atherosclerosis. The drug is primarily developed and studied by researchers at Fangshan Hospital of Beijing University of Chinese Medicine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tiaozhi tongmai granule.